Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have rapidly transformed the management of type 2 diabetes mellitus (T2DM) and obesity. Beyond glycemic control, this class now offers FDA-approved indications for cardiovascular risk reduction, obstructive sleep apnea, and liver disease. As their use continues to expand, pharmacists and pharmacy technicians play a crucial role in patient education, medication counseling, titration support, and monitoring for adverse effects.

This guide provides a concise yet comprehensive overview of GLP-1 RAs — including mechanism of action, common side effects, all currently available agents, and updated counseling points reflecting approvals through mid-2026.

Mechanism of Action (MOA)

GLP-1 receptor agonists mimic the incretin hormone GLP-1, enhancing insulin regulation and metabolic control through several pathways:

1. Glucose-Dependent Insulin Secretion

GLP-1 RAs stimulate pancreatic β-cells to release insulin only when blood glucose is elevated, reducing the risk of hypoglycemia.

2. Suppression of Glucagon

They inhibit glucagon secretion from α-cells, decreasing hepatic glucose output during hyperglycemia.

3. Delayed Gastric Emptying

By slowing gastric motility, GLP-1 agents reduce postprandial glucose spikes and promote early satiety — key in weight reduction. Note: this effect may reduce absorption of other oral medications taken concomitantly.

4. Central Appetite Regulation

GLP-1 receptors in the hypothalamus decrease appetite and caloric intake, driving the significant weight loss seen with newer high-dose agents.

5. Cardioprotective Effects EXPANDED 2024–2026

Several agents now carry dedicated FDA-approved cardiovascular indications, supported by landmark outcome trials:

• Liraglutide (Victoza) — CV risk reduction in T2DM with established CVD (LEADER trial)
• Semaglutide SC (Ozempic) — CV risk reduction in T2DM with established CVD (SUSTAIN-6 trial)
• Dulaglutide (Trulicity) — CV risk reduction in T2DM (REWIND trial)
• Semaglutide SC (Wegovy injection) — CV risk reduction in adults with obesity/overweight and established CVD, approved March 2024 (SELECT trial) — the first weight loss drug ever approved for this indication
• Semaglutide oral (Wegovy pill) — CV risk reduction indication, approved December 2025
• Semaglutide oral (Rybelsus 7 mg / 14 mg) — CV risk reduction added October 2025 for T2DM patients at high CV risk

Mechanisms include improved endothelial function, weight loss, reduced inflammation, and direct cardiac effects independent of glycemic control.

6. Emerging Indications

Research continues to explore GLP-1 benefits in Alzheimer's disease, Parkinson's disease, non-alcoholic fatty liver disease, alcohol use disorder, chronic kidney disease, and obstructive sleep apnea — with several already receiving FDA approval or accelerated approval.

Common Side Effects

Most adverse effects are gastrointestinal and dose-dependent, especially during titration:

Gastrointestinal

• Nausea (most common — especially during dose escalation)
• Vomiting
• Diarrhea
• Constipation
• Dyspepsia, abdominal pain, belching

These often improve significantly with slow dose escalation and typically resolve within the first 4–8 weeks of a stable dose.

Endocrine / Metabolic

• Hypoglycemia (rare unless combined with insulin or sulfonylureas)
• Reduced appetite and caloric intake
• Muscle mass loss with significant weight reduction — encourage adequate protein intake and resistance exercise

Injection-Site Reactions

• Erythema, pruritus, small nodules — rotate injection sites with every dose
• Dysesthesia (tingling or altered skin sensation) — reported in ~22% of patients on Wegovy HD 7.2 mg vs 6% on standard dose

Serious but Less Common

• Pancreatitis — counsel patients to report persistent abdominal pain radiating to the back; discontinue immediately if suspected
• Gallbladder disease — increased incidence of gallstones with rapid weight loss
• Acute kidney injury from dehydration secondary to GI losses — maintain hydration especially during titration
• Diabetic retinopathy worsening — monitor in patients with pre-existing retinopathy, particularly with rapid A1c improvement
• Thyroid C-cell tumors — boxed warning for most agents in this class based on rodent data; human relevance undetermined; contraindicated in patients with personal or family history of MTC or MEN2

Weight Loss (Expected Pharmacologic Effect)

Seen widely across the class; varies by agent and dose — ranges from ~6% (exenatide) to ~22.5% mean body weight reduction (tirzepatide 15 mg).

GLP-1 Medications at a Glance — Full Reference Table

Commonly Prescribed GLP-1 Medications — Detailed Profiles

1. Liraglutide (Victoza®, Saxenda®) GENERICS AVAILABLE

• Form: Daily SC injection
• Indications: T2DM (Victoza); chronic weight management (Saxenda)
• Generics: Generic liraglutide referencing Victoza approved December 2024 — first generic GLP-1 for T2DM in the US. Generic liraglutide 3 mg referencing Saxenda approved August 2025 — first generic GLP-1 for weight management in the US.
• Notes: Proven cardiovascular benefit; slower titration reduces GI effects. Arrival of generics significantly reduces cost for eligible patients.

2. Dulaglutide (Trulicity®)

• Form: Once-weekly SC injection
• Indications: T2DM; CV risk reduction
• Notes: User-friendly single-dose auto-injector requires no mixing or assembly. Strong cardiovascular outcomes data (REWIND trial). Generics expected around 2027.

3. Semaglutide MULTIPLE NEW APPROVALS

Semaglutide is now available in more formulations than any other GLP-1 agent:

• Ozempic® — Weekly SC injection for T2DM; CV risk reduction
• Rybelsus® — Daily oral tablet for T2DM; CV risk reduction added October 2025; must be taken on empty stomach with ≤4 oz water, 30 minutes before eating or taking other medications
• Wegovy® injection — Weekly SC injection for chronic weight management; CV risk reduction (March 2024); MASH treatment with accelerated approval (August 2025); approved ages 12+
• Wegovy® pill — Once-daily oral tablet (25 mg); first oral GLP-1 approved specifically for weight management; approved December 2025; CV risk reduction also indicated; taken in the morning with water — no 30-minute fast required
• Wegovy HD® — Weekly SC injection (7.2 mg); highest-dose injectable semaglutide ever approved; approved March 2026; step-up only for patients who have tolerated 2.4 mg for at least 4 weeks; ~20.7% mean weight loss at 72 weeks in STEP UP trial; monitor for dysesthesia

Among the most potent agents for A1c reduction and weight loss. Note that Wegovy pill and Rybelsus are different products with different indications and different administration requirements — they are not interchangeable.

4. Tirzepatide (Mounjaro®, Zepbound®) OSA INDICATION ADDED

Technically a dual GIP/GLP-1 receptor agonist but used clinically within the same therapeutic space.

• Form: Weekly SC injection
• Indications: T2DM (Mounjaro); chronic weight management (Zepbound); moderate-to-severe obstructive sleep apnea in adults with obesity (Zepbound, December 2024) — the first FDA-approved drug treatment for OSA ever
• Notes: Synergistic GLP-1 and GIP receptor activity produces the greatest weight loss of any currently approved agent — up to ~22.5% mean body weight reduction at the 15 mg dose. CV indication for Mounjaro under FDA review, decision expected mid-2026.

6. Exenatide (Byetta®, Bydureon BCise®) BRANDS DISCONTINUED

• Byetta — Twice-daily SC injection; brand discontinued by AstraZeneca October 2024. Generic exenatide (Amneal) approved November 2024 — the first generic for any GLP-1 receptor agonist in US history. Generic launched November 2024 and remains available.
• Bydureon BCise — Weekly SC injection; brand also discontinued October 2024. No generic currently available.
• Notes: Older agent; GI side effects common; use caution in renal impairment (eGFR <30 mL/min). Despite brand discontinuation, generic exenatide remains a lower-cost option for appropriate patients.

7. Lixisenatide (Adlyxin®)

• Form: Once-daily SC injection
• Indications: T2DM
• Notes: Often combined with insulin glargine in Soliqua® (insulin glargine/lixisenatide). Older agent with limited standalone use in current practice given availability of more efficacious alternatives.

Key Counseling Points for Pharmacy Staff

Administration and Titration

• Start low and go slow: GI intolerance improves significantly over time with gradual titration. Never rush escalation. Patients who discontinue due to nausea within the first few weeks may simply need a slower titration schedule.
• Oral GLP-1 administration varies by product — they are NOT the same:
  • Rybelsus: Empty stomach, ≤4 oz plain water only, wait 30 minutes before eating or taking any other medications or beverages.
  • Wegovy pill: Take in the morning with water — no food restriction required but take consistently at the same time each day.
  • Foundayo: Any time of day, with or without food, no water restrictions. Most flexible oral GLP-1 option.
• Wegovy HD is a step-up, not a start: The 7.2 mg high-dose semaglutide injection is approved only for patients who have already tolerated 2.4 mg for at least 4 weeks and require additional weight reduction. Counsel prescribers and patients clearly — this is never an appropriate starting dose.
• Missed doses: Encourage patients to follow manufacturer-specific guidelines. For weekly injections, missed doses can generally be taken within 5 days; after that, skip and resume on the usual day.

Storage

• Most injectable pens must be refrigerated until first use, then can be kept at room temperature — but time at room temperature varies by product (14 days for some, 28–56 days for others). Always confirm with the specific product's prescribing information.
• Never freeze any GLP-1 product. Frozen pens are damaged and must be discarded.
• Keep pens away from direct sunlight and heat sources.

Drug Interactions and Combination Therapy

• Combination therapy caution: Hypoglycemia risk increases when combined with insulin or sulfonylureas. Dose reduction of the insulin or sulfonylurea is often warranted when initiating GLP-1 therapy.
• Do not combine GLP-1 agents: Using more than one GLP-1 receptor agonist simultaneously is not recommended. With multiple oral and injectable options now available, patients may attempt to use products interchangeably or concurrently — counsel clearly against this.
• Oral medication absorption: Delayed gastric emptying can reduce absorption of other oral medications. Time-sensitive drugs (oral contraceptives, thyroid medications, antibiotics) should be taken at least 1 hour before GLP-1 injection where possible.

Safety Monitoring

• Thyroid cancer warning: Avoid in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Counsel patients to report any neck lump, hoarseness, or difficulty swallowing.
• Pancreatitis: Counsel patients to report severe, persistent abdominal pain — especially if it radiates to the back. Discontinue immediately if pancreatitis is suspected.
• Hydration: Prevent dehydration during early titration when nausea and vomiting are most common. Dehydration can precipitate acute kidney injury.
• Diabetic retinopathy: Rapid A1c improvement has been associated with worsening of pre-existing diabetic retinopathy. Ophthalmologic monitoring is recommended in at-risk patients.

New Indications — Expand Patient Counseling Scope

• Obstructive sleep apnea (Zepbound): Patients prescribed Zepbound for OSA may not associate it with a GLP-1 medication. Counsel on the same GI side effects, injection technique, and thyroid cancer warning — the drug is the same regardless of indication.
• MASH (Wegovy): Wegovy's MASH approval is accelerated — meaning continued approval depends on confirmatory trial results. Counsel prescribers that this remains under post-marketing study.
• Muscle mass preservation: Significant weight loss with higher-dose agents can include loss of lean muscle mass alongside fat. Encourage adequate protein intake and resistance exercise throughout therapy to preserve muscle.

Access, Cost, and Generics

• Generics are now available: Generic exenatide, generic liraglutide (T2DM), and generic liraglutide 3 mg (weight management) are now FDA-approved. Counsel patients that generics contain the same active ingredient and offer significant cost savings. Help patients understand their options.
• Compounded semaglutide is being phased out: FDA enforcement actions beginning in early 2026 ended the availability of most compounded semaglutide products. Patients previously using compounded versions need to transition to FDA-approved products — assist with the transition and prior authorization as needed.
• Prior authorization requirements: GLP-1 agents for weight management — especially newer agents — often require prior authorization with documented BMI thresholds and comorbidities. Proactively prepare documentation and identify manufacturer savings programs to reduce patient out-of-pocket costs.

Conclusion

GLP-1 receptor agonists have evolved from a diabetes drug class into one of the most expansive and rapidly advancing areas of modern pharmacotherapy. Their benefits now span glucose control, weight reduction, cardiovascular protection, liver disease, and obstructive sleep apnea — with new indications, formulations, and agents continuing to emerge at an unprecedented pace.

Since 2024 alone, the class has gained the first oral GLP-1 for weight management (Wegovy pill, December 2025), the first non-peptide oral GLP-1 (Foundayo/orforglipron, April 2026), the highest-dose injectable semaglutide ever approved (Wegovy HD 7.2 mg, March 2026), the first drug treatment for obstructive sleep apnea (Zepbound, December 2024), the first GLP-1 approval for a liver disease (Wegovy for MASH, August 2025), and the first generics for the entire drug class (2024–2025).

Pharmacists and pharmacy technicians are uniquely positioned to optimize therapy by counseling on proper administration — which now varies significantly by product — managing expectations regarding side effects, supporting patients through titration, navigating insurance and prior authorization requirements, and helping patients transition from compounded products to FDA-approved alternatives. As this class continues to expand, staying current is not optional — it is essential to safe and effective patient care.